Bicara Therapeutics (NASDAQ:BCAX) Sets New 1-Year High on Analyst Upgrade

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) reached a new 52-week high on Wednesday after The Goldman Sachs Group raised their price target on the stock from $14.00 to $16.00. The Goldman Sachs Group currently has a neutral rating on the stock. Bicara Therapeutics traded as high as $21.05 and last traded at $20.5040, with a volume of 90918 shares changing hands. The stock had previously closed at $19.89.

Several other research firms also recently commented on BCAX. Bank of America initiated coverage on Bicara Therapeutics in a research report on Wednesday, March 25th. They set a “buy” rating and a $35.00 target price for the company. Mizuho upgraded Bicara Therapeutics to a “hold” rating in a research note on Thursday, December 18th. Wells Fargo & Company increased their price objective on Bicara Therapeutics from $11.00 to $16.00 and gave the stock an “equal weight” rating in a research note on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Friday, January 9th. Finally, Wedbush restated an “outperform” rating and issued a $30.00 target price on shares of Bicara Therapeutics in a research note on Tuesday. Eight research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $28.00.

Insider Activity

In related news, insider David Raben sold 16,300 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $18.52, for a total transaction of $301,876.00. Following the completion of the sale, the insider directly owned 55,286 shares of the company’s stock, valued at $1,023,896.72. This trade represents a 22.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Claire Mazumdar sold 36,766 shares of Bicara Therapeutics stock in a transaction on Monday, March 9th. The shares were sold at an average price of $19.17, for a total value of $704,804.22. Following the completion of the transaction, the chief executive officer owned 339,392 shares of the company’s stock, valued at approximately $6,506,144.64. The trade was a 9.77% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 137,969 shares of company stock worth $2,586,198. 15.50% of the stock is currently owned by insiders.

More Bicara Therapeutics News

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Wall Street analyst consensus implies a large upside (~54.9%) to BCAX based on average price targets and improving earnings-estimate revisions, a factor traders cite as justification for buying interest. Wall Street Analysts Believe Bicara Therapeutics Inc. (BCAX) Could Rally 54.85%: Here’s is How to Trade
• Positive Sentiment: Clinical progress: Seeking Alpha reiterates a Buy rating as BCAX advances its pivotal phase 3 FORTIFI-HN01 study; strong phase 1/1b signals (12‑month OS 61%, ORR 54% with ficerafusp alfa + KEYTRUDA) support the program. Key upcoming catalysts: phase‑3 interim readout mid‑2027 and long‑term phase 1b follow‑up at ASCO 2026. Near‑full enrollment expected by year‑end. Bicara: Maintaining ‘Buy’ Rating On Ficerafusp Alfa Phase 3 Advancement
• Positive Sentiment: Q4 / cash position: Earnings call highlights show a stronger cash position and a slight beat on Q4 EPS vs. estimates, which reduces near‑term dilution risk and supports runway for clinical execution. Bicara Therapeutics Inc (BCAX) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Full Q4 earnings call transcript is available for investors digging into management comments on timelines and cash burn; useful for detailed diligence but not a single price driver by itself. Q4 2025 earnings call transcript
• Negative Sentiment: Mixed analyst views: Goldman Sachs raised its PT to $16 (neutral) and Wells Fargo to $16 (equal‑weight)—both targets sit well below the current market price, implying downside from their perspective. These conservative calls can cap near‑term upside and add volatility. Benzinga coverage of analyst moves
• Positive Sentiment: Other broker support remains bullish: Wedbush (outperform, $30 PT), Citizens Jmp (market outperform, $31 PT) and HC Wainwright (buy, PT $42) provide higher upside scenarios that likely underlie investor optimism. Benzinga coverage of analyst moves

Institutional Trading of Bicara Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in BCAX. Mirae Asset Global Investments Co. Ltd. acquired a new position in Bicara Therapeutics during the 4th quarter worth about $45,000. Legal & General Group Plc increased its position in Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after acquiring an additional 1,233 shares in the last quarter. Ameritas Investment Partners Inc. raised its stake in shares of Bicara Therapeutics by 73.0% in the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock worth $32,000 after acquiring an additional 1,474 shares during the last quarter. Larson Financial Group LLC lifted its position in shares of Bicara Therapeutics by 1,015.5% during the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after purchasing an additional 3,595 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in shares of Bicara Therapeutics by 419.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after purchasing an additional 3,866 shares in the last quarter.

Bicara Therapeutics Price Performance

The company’s 50 day moving average price is $17.28 and its 200 day moving average price is $16.69. The firm has a market capitalization of $1.34 billion, a P/E ratio of -8.10 and a beta of -1.24.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings results on Monday, March 30th. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.04. On average, research analysts anticipate that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.